American journal of neurodegenerative disease最新文献_第7页

Comparison of two methods for the analysis of CSF Aβ and tau in the diagnosis of Alzheimer's disease. 脑脊液Aβ和tau两种分析方法在阿尔茨海默病诊断中的比较。

American journal of neurodegenerative disease Pub Date : 2014-12-05 eCollection Date: 2014-01-01

Matthew Faull, Simon Yl Ching, Anna I Jarmolowicz, John Beilby, Peter K Panegyres

{"title":"Comparison of two methods for the analysis of CSF Aβ and tau in the diagnosis of Alzheimer's disease.","authors":"Matthew Faull, Simon Yl Ching, Anna I Jarmolowicz, John Beilby, Peter K Panegyres","doi":"","DOIUrl":"","url":null,"abstract":"Introduction: Biomarkers represent a promising adjunct to clinical techniques in the diagnosis of Alzheimer's Disease (AD) and other neurodegenerative diseases. At present, the potential of cerebrospinal fluid (CSF) biomarkers in diagnosing AD has been suggested but the degree of clinical utility is yet to be defined due to variability between studies. In this paper we compare the performance of two cerebrospinal fluid assay methods in predicting clinically diagnosed AD.Methods: CSF biomarker concentrations for Aβ1-42, P-tau181P and T-tau were analysed using INNOTEST (ELISA) and INNO-BIA AlzBio3 (Luminex) assay methods from Innogenetics, Belgium. Patients were clinically diagnosed based on NINCDS-ADRDA criteria supplemented with structural MRI, (18)F-fluorodeoxy-glucose positron emission tomography (FDG-PET) and cognitive profiling.Results: An abnormally low Aβ1-42 was the most useful biomarker in predicting clinical AD. Depending on the assay method, the predictive accuracy remained constant or improved slightly when abnormalities in P-tau181P and T-tau were considered in addition to Aβ1-42. The Luminex method with our optimised reference concentrations performed best for patients ≤ 65 years with sensitivity = 1 and a specificity = 0.60 for both Aβ1-42 and when one or more abnormal biomarkers were considered.Conclusion: Given accurate, robust and reproducible CSF analytical methods, of which the Luminex method seems the most useful and practicable, our investigation suggests that measuring CSF Aβ1-42, P-tau and T-tau has utility in the diagnosis of probable AD and, when used with clinical diagnostic techniques, seems especially helpful in the diagnosis of AD with onset prior to the age of 65 years.","PeriodicalId":72170,"journal":{"name":"American journal of neurodegenerative disease","volume":"3 3","pages":"143-51"},"PeriodicalIF":0.0,"publicationDate":"2014-12-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4299722/pdf/ajnd0003-0143.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33009830","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Greater loss of von Economo neurons than loss of layer II and III neurons in behavioral variant frontotemporal dementia. 行为变异性额颞叶痴呆中von Economo神经元的损失大于II和III层神经元的损失。

American journal of neurodegenerative disease Pub Date : 2014-09-06 eCollection Date: 2014-01-01

Alexander F Santillo, Elisabet Englund

{"title":"Greater loss of von Economo neurons than loss of layer II and III neurons in behavioral variant frontotemporal dementia.","authors":"Alexander F Santillo, Elisabet Englund","doi":"","DOIUrl":"","url":null,"abstract":"Previous studies have shown a selective reduction of von Economo neurons (VENs) in behavioral variant frontotemporal dementia (bvFTD). However, the alleged selectivity rests on the comparison between VENs and other neurons in cortical layer V, while it has been established that neurons in the superficial cortical layers (I-III) are particularly affected in bvFTD. The purpose of this study was to examine loss the loss of VENs in comparison with that of non-VEN-neurons of superficial cortical layers. VENs and non-VEN-neurons of cortical layer V and layers II+III were quantified in the anterior cingulate cortex in 16 cases of bvFTD, 12 non-demented controls and 10 cases of Alzheimer's disease (AD). In bvFTD VENs were more depleted than non-VEN-neurons of layers V and II+III. Also, non-VEN-neurons of layer II+III showed a greater density reduction than those of layer V in bvFTD. VEN density was also reduced in AD, albeit to a lesser extent than in bvFTD, and the differences between bvFTD and AD were only significant when relating VEN loss to that of layer V neurons. Our study strengthens the view of VENs as a particularly sensitive neuronal type of bvFTD, and appears to be on a continuum with the loss of other neurons both in bvFTD and between conditions. ","PeriodicalId":72170,"journal":{"name":"American journal of neurodegenerative disease","volume":"3 2","pages":"64-71"},"PeriodicalIF":0.0,"publicationDate":"2014-09-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4162587/pdf/ajnd0003-0064.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"32677469","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Omental transplantation for neurodegenerative diseases. 网膜移植治疗神经退行性疾病。

American journal of neurodegenerative disease Pub Date : 2014-09-06 eCollection Date: 2014-01-01

Hernando Rafael

引用次数: 0

Alpha rhythm oscillations and MMSE scores are differently modified by transdermal or oral rivastigmine in patients with Alzheimer's disease. 阿尔茨海默病患者的阿尔法节律振荡和 MMSE 评分在经皮或口服利伐斯的明治疗后有不同程度的改变。

American journal of neurodegenerative disease Pub Date : 2014-09-06 eCollection Date: 2014-01-01

Davide V Moretti

{"title":"Alpha rhythm oscillations and MMSE scores are differently modified by transdermal or oral rivastigmine in patients with Alzheimer's disease.","authors":"Davide V Moretti","doi":"","DOIUrl":"","url":null,"abstract":"Background: Alzheimer's disease (AD) is the most common cause of dementia in older patients. Rivastigmine, a reversible cholinesterase inhibitor, has been shown to improve the clinical manifestations of AD by delaying the breakdown of acetylcholine (ACh) released into synaptic clefts. Moreover, there is evidence that ACh modulates EEG alpha frequency.Objectives: the objectives of this pilot study in patients with AD were to determine the effects of two formulations of RV (transdermal and oral) on Mini-Mental State Examination (MMSE) scores and on alpha frequency in particular the posterior dominant rhythm.Methods: twenty subjects with AD were randomly assigned to receive either RV transdermal patch (RV-TDP, n=10) or RV capsules (RV-CP, n=10) according to the standard recommended dosage regimen. All patients were driven to the maximum drug dosage. Diagnosis of AD was made according to NINCDS-ADRDA criteria and the Diagnostic and Statistical Manual of Mental Disorders IV. All patients underwent EEG recordings at the beginning and at the end of the 18-month study period using P3, P4, O1 and O2 electrodes each at high (10.5-13.0 Hz) and low (8.0-10.5 Hz) frequency. MMSE scores were determined at the start of the study and at three successive 6-month intervals (T0, T1, T2, and T3).Results: administration of RV-DP increases the spectral power of alpha waves in the posterior region and is associated with improved cognitive function as evidenced by significant changes in MMSE scores.Conclusion: RV-DP provides an effective and long-term management option in patients with AD.","PeriodicalId":72170,"journal":{"name":"American journal of neurodegenerative disease","volume":"3 2","pages":"72-83"},"PeriodicalIF":0.0,"publicationDate":"2014-09-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4162588/pdf/ajnd0003-0072.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"32677470","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Optineurin immunoreactivity in neuronal and glial intranuclear inclusions in adult-onset neuronal intranuclear inclusion disease. 成人发病的神经元核内包涵体病中神经元和胶质核内包涵体中的视神经蛋白免疫反应性

American journal of neurodegenerative disease Pub Date : 2014-09-06 eCollection Date: 2014-01-01

Masataka Nakamura, Melissa E Murray, Wen-Lang Lin, Hirofumi Kusaka, Dennis W Dickson

{"title":"Optineurin immunoreactivity in neuronal and glial intranuclear inclusions in adult-onset neuronal intranuclear inclusion disease.","authors":"Masataka Nakamura, Melissa E Murray, Wen-Lang Lin, Hirofumi Kusaka, Dennis W Dickson","doi":"","DOIUrl":"","url":null,"abstract":"Optineurin (OPTN) is a multifunctional protein involved in cellular morphogenesis, vesicle trafficking, maintenance of the Golgi complex, and transcription activation through its interactions with the Rab8, myosin 6 (MYO6), huntingtin. Recently, OPTN immunoreactivity has been reported in intranuclear inclusions in patients with neuronal intranuclear inclusions disease (NIID). Other studies have shown that the RNA-binding protein, fused in sarcoma (FUS), is a component of intranuclear inclusions in NIID. We aimed to investigate the relationship between OPTN, its binding protein MYO6 and FUS in this study. In control subjects, OPTN (C-terminal) (OPTN-C) and MYO6 immunoreactivity was mainly demonstrated in the cytoplasm of neurons. In NIID patients, both neuronal intranuclear inclusions (NII) and glial intranuclear inclusions (GII) were immunopositive for MYO6 as well as OPTN-C. However, the intensity of OPTN-C immunostaining of the neuronal cytoplasm with and without NII was less than that of the control subjects. Double immunofluorescence staining for OPTN-C, ubiquitin (Ub), p62 and FUS revealed co-localization of these proteins within NII. Moreover, Ub positive inclusions were co-localized with MYO6. The percentage of co-localization of Ub with OPTN-C, FUS or MYO6 in NII was 100%, 52% and 92%, respectively. Ultrastructurally, the inclusions consisted of thin and thick filaments. Both filaments were immunopositive for Ub and OPTN-C. These findings suggest that OPTN plays a central role in the disease pathogenesis, and that OPTN may be a major component of NII. ","PeriodicalId":72170,"journal":{"name":"American journal of neurodegenerative disease","volume":"3 2","pages":"93-102"},"PeriodicalIF":0.0,"publicationDate":"2014-09-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4162590/pdf/ajnd0003-0093.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"32677472","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Somatic complaints in frontotemporal dementia. 额颞叶痴呆的躯体主诉。

American journal of neurodegenerative disease Pub Date : 2014-09-06 eCollection Date: 2014-01-01

Maria Landqvist Waldö, Alexander Frizell Santillo, Lars Gustafson, Elisabet Englund, Ulla Passant

{"title":"Somatic complaints in frontotemporal dementia.","authors":"Maria Landqvist Waldö, Alexander Frizell Santillo, Lars Gustafson, Elisabet Englund, Ulla Passant","doi":"","DOIUrl":"","url":null,"abstract":"Frontotemporal dementia (FTD) is associated with a broad spectrum of clinical characteristics. The objective of this study was to analyze the prevalence of unexplained somatic complaints in neuropathologically verified FTD. We also examined whether the somatic presentations correlated with protein pathology or regional brain pathology and if the patients with these somatic features showed more depressive traits. Ninety-seven consecutively neuropathologically verified FTLD patients were selected. All 97 patients were part of a longitudinal study of FTD and all medical records were systematically reviewed. The somatic complaints focused on were headache, musculoskeletal, gastro/urogenital and abnormal pain response. Symptoms of somatic character (either somatic complaints and/or abnormal pain response) were found in 40.2%. These patients did not differ from the total group with regard to gender, age at onset or duration. Six patients showed exaggerated reactions to sensory stimuli, whereas three patients showed reduced response to pain. Depressive traits were present in 38% and did not correlate with somatic complaints. Suicidal behavior was present in 17 patients, in 10 of these suicidal behavior was concurrent with somatic complaints. No clear correlation between somatic complaints and brain protein pathology, regional pathology or asymmetric hemispherical atrophy was found. Our results show that many FTD patients suffer from unexplained somatic complaints before and/or during dementia where no clear correlation can be found with protein pathology or regional degeneration. Somatic complaints are not covered by current diagnostic criteria for FTD, but need to be considered in diagnostics and care. The need for prospective studies with neuropathological follow up must be stressed as these phenomena remain unexplained, misinterpreted, bizarre and, in many cases, excruciating. ","PeriodicalId":72170,"journal":{"name":"American journal of neurodegenerative disease","volume":"3 2","pages":"84-92"},"PeriodicalIF":0.0,"publicationDate":"2014-09-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4162589/pdf/ajnd0003-0084.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"32677471","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Validation of an Alzheimer's disease assessment battery in Asian participants with mild to moderate Alzheimer's disease. 在患有轻度至中度阿尔茨海默病的亚洲参与者中，阿尔茨海默病评估电池的验证

American journal of neurodegenerative disease Pub Date : 2014-07-28 DOI: 10.4172/2167-7182.1000167

J. Shen, Qi Shen, Holly Yu, J. Lai, J. Beaumont, Zhenxin Zhang, Huali Wang, S. Kim, Christopher Chen, T. Kwok, Shuu-Jiun Wang, D. Y. Lee, J. Harrison, J. Cummings

{"title":"Validation of an Alzheimer's disease assessment battery in Asian participants with mild to moderate Alzheimer's disease.","authors":"J. Shen, Qi Shen, Holly Yu, J. Lai, J. Beaumont, Zhenxin Zhang, Huali Wang, S. Kim, Christopher Chen, T. Kwok, Shuu-Jiun Wang, D. Y. Lee, J. Harrison, J. Cummings","doi":"10.4172/2167-7182.1000167","DOIUrl":"https://doi.org/10.4172/2167-7182.1000167","url":null,"abstract":"There is a lack of validated tools for assessing Alzheimer's disease (AD) across Asia. This study evaluates the psychometric properties of the Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog), Disability Assessment for Dementia (DAD), and Neuropsychological Test Battery (NTB) in Asian participants. Participants with mild to moderate AD (n=251) and healthy controls (n=51) from Mainland China, Taiwan, Singapore, Hong Kong, and South Korea completed selected instruments at several time points. Test-retest reliability was better than 0.70 for all tests. AD participants performed significantly more poorly than controls on every score. Within the AD group, greater disease severity corresponded to significantly poorer performance. The AD group test performance worsened over time and there was a trend for worse performance in AD compared to healthy controls over time. The ADAS-Cog, DAD, and NTB are reliable, valid, and responsive measures in this population and could be used for clinical trials across Asian countries/regions.","PeriodicalId":72170,"journal":{"name":"American journal of neurodegenerative disease","volume":"3 3 1","pages":"158-69"},"PeriodicalIF":0.0,"publicationDate":"2014-07-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.4172/2167-7182.1000167","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"70828961","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 20

Identification of microRNAs involved in Alzheimer's progression using a rabbit model of the disease. 利用兔阿尔茨海默病模型鉴定参与阿尔茨海默病进展的microrna。

American journal of neurodegenerative disease Pub Date : 2014-03-28 eCollection Date: 2014-01-01

Qing Yan Liu, Marilyn N Vera Chang, Joy X Lei, Roger Koukiekolo, Brandon Smith, Dongling Zhang, Othman Ghribi

{"title":"Identification of microRNAs involved in Alzheimer's progression using a rabbit model of the disease.","authors":"Qing Yan Liu, Marilyn N Vera Chang, Joy X Lei, Roger Koukiekolo, Brandon Smith, Dongling Zhang, Othman Ghribi","doi":"","DOIUrl":"","url":null,"abstract":"Alzheimer's disease (AD) is the most common neurodegenerative disorder characterized by the presence of extracellular plaques of β-amyloid peptides and intracellular tangles of hyperphosphorylated tau proteins in the brain. The vast majority of cases are late onset AD (LOAD), which are genetically heterogeneous and occur sporadically. High blood cholesterol is suggested to be a risk factor for this disease. Several neuropathological changes of LOAD can be reproduced by supplementing a rabbit's diet with 2% cholesterol for 12 weeks. Accumulating data in the literature suggest that microRNAs (miRNA) participate in the development of AD pathology. The present study focuses on the survey of changes of miRNA expression in rabbit brains during the progression of AD-like pathology using microarray followed by Taq-Man qRT-PCR analyses. Out of 1769 miRNA probes used in the experiments, 99 miRNAs were found to be present in rabbit brain, 57 were newly identified as miRNAs from rabbit brain. Eleven miRNAs showed significant changes over AD-like pathology progression. Among them, the changes of miR-125b, miR-98, miR-107, miR-30, along with 3 members of the let-7 family were similar to those observed in human AD samples, whereas the expression patterns of miR-15a, miR-26b, miR-9 and miR-576-3p were unique to this rabbit LOAD model. The significant up regulation of miR-26b is consistent with the decrease of leptin levels in the brains of cholesterol fed rabbit model for AD, confirming that miR-26b is indeed regulated by leptin and that both leptin and miR-26b may be involved in cholesterol induced AD-like pathology. ","PeriodicalId":72170,"journal":{"name":"American journal of neurodegenerative disease","volume":"3 1","pages":"33-44"},"PeriodicalIF":0.0,"publicationDate":"2014-03-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3986609/pdf/ajnd0003-0033.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"32280251","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Neuropathologic correlates of trial-related instruments for Alzheimer's disease. 阿尔茨海默病试验相关仪器的神经病理学相关性

American journal of neurodegenerative disease Pub Date : 2014-03-28 eCollection Date: 2014-01-01

Jeffrey L Cummings, John Ringman, Harry V Vinters

{"title":"Neuropathologic correlates of trial-related instruments for Alzheimer's disease.","authors":"Jeffrey L Cummings, John Ringman, Harry V Vinters","doi":"","DOIUrl":"","url":null,"abstract":"To advance disease-modifying therapies, it is critical to understand the relationship between the neuropathological changes of Alzheimer's Disease (AD) and the clinical measures used in therapeutic trials. We reviewed neuropathologically proven cases of AD from the National Alzheimer's Coordinating Center (NACC) and examined correlations between neuropathological changes and clinical-trial related instruments collected as part of the Uniform Dataset (UDS). We explored the relationships between neurofibrillary tangles, neuritic plaques, and total pathology burden with immediate and delayed recall, Clinical Dementia Rating-Sum of Boxes, Functional Activity Questionnaire, Neuropsychiatric Inventory Questionnaire, and Mini-Mental State Examination scores. 169 patients in NACC database had appropriate neuropathological and clinical data. All instruments correlated highly with neuritic plaques, Braak staging, and total pathology. Correlation coefficients for the relationships were relatively modest, suggesting that the pathologic burden examined accounts for between 13 and 40% of the variance of each of the instruments assessed. We conclude that there is a strong correlation between clinical trial-related measures and neuropathology identified at autopsy in AD. The amount of variance explained by the pathology is limited and other factors, both disease- and measurement-related, contribute to the variability observed in clinical measurements. ","PeriodicalId":72170,"journal":{"name":"American journal of neurodegenerative disease","volume":"3 1","pages":"45-9"},"PeriodicalIF":0.0,"publicationDate":"2014-03-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3986610/pdf/ajnd0003-0045.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"32280252","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Development, appraisal, validation and implementation of a consensus protocol for the assessment of cerebral amyloid angiopathy in post-mortem brain tissue. 制定、评估、验证和实施用于评估死后脑组织中脑淀粉样血管病的共识协议。

American journal of neurodegenerative disease Pub Date : 2014-03-28 eCollection Date: 2014-01-01

Seth Love, Katy Chalmers, Paul Ince, Margaret Esiri, Johannes Attems, Kurt Jellinger, Masahito Yamada, Mark McCarron, Thais Minett, Fiona Matthews, Steven Greenberg, David Mann, Patrick Gavin Kehoe

{"title":"Development, appraisal, validation and implementation of a consensus protocol for the assessment of cerebral amyloid angiopathy in post-mortem brain tissue.","authors":"Seth Love, Katy Chalmers, Paul Ince, Margaret Esiri, Johannes Attems, Kurt Jellinger, Masahito Yamada, Mark McCarron, Thais Minett, Fiona Matthews, Steven Greenberg, David Mann, Patrick Gavin Kehoe","doi":"","DOIUrl":"","url":null,"abstract":"In a collaboration involving 11 groups with research interests in cerebral amyloid angiopathy (CAA), we used a two-stage process to develop and in turn validate a new consensus protocol and scoring scheme for the assessment of CAA and associated vasculopathic abnormalities in post-mortem brain tissue. Stage one used an iterative Delphi-style survey to develop the consensus protocol. The resultant scoring scheme was tested on a series of digital images and paraffin sections that were circulated blind to a number of scorers. The scoring scheme and choice of staining methods were refined by open-forum discussion. The agreed protocol scored parenchymal and meningeal CAA on a 0-3 scale, capillary CAA as present/absent and vasculopathy on 0-2 scale, in the 4 cortical lobes that were scored separately. A further assessment involving three centres was then undertaken. Neuropathologists in three centres (Bristol, Oxford and Sheffield) independently scored sections from 75 cases (25 from each centre) and high inter-rater reliability was demonstrated. Stage two used the results of the three-centre assessment to validate the protocol by investigating previously described associations between APOE genotype (previously determined), and both CAA and vasculopathy. Association of capillary CAA with or without arteriolar CAA with APOE ε4 was confirmed. However APOE ε2 was also found to be a strong risk factor for the development of CAA, not only in AD but also in elderly non-demented controls. Further validation of this protocol and scoring scheme is encouraged, to aid its wider adoption to facilitate collaborative and replication studies of CAA. ","PeriodicalId":72170,"journal":{"name":"American journal of neurodegenerative disease","volume":"3 1","pages":"19-32"},"PeriodicalIF":0.0,"publicationDate":"2014-03-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3986608/pdf/ajnd0003-0019.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"32279796","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0